Search by keywords: Connect with us Stay Informed. Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters. Newsletter Sign Up 1822 News Items found The Future of Immunotherapy Research at MSK: A Conversation With Dr. Andy Minn, Chair of MSK’s New Immuno-Oncology Program Wednesday, October 15, 2025 Dr. Andy Minn, the inaugural chair of MSK's Immuno-Oncology Program, discusses his vision for the program and what it means for patients. How Routine Prenatal Tests Can Detect Cancer and What It Means for Pregnant Women Monday, October 6, 2025 Learn how noninvasive prenatal tests designed to screen for genetic abnormalities in the fetus may detect the presence of cancer in pregnant women. In the Lab New Research Helps Model How the Immune System Shapes Cancer Development Monday, October 6, 2025 Read about MSK research that sheds light on how the innate immune system interacts with developing cancer cells. What Is Invasive Lobular Carcinoma? MSK Doctors Explain Thursday, October 2, 2025 Learn about how MSK’s new Lobular Breast Cancer Program is working to improve outcomes for people with invasive lobular breast cancer and other types of LBC. ASTRO 2025 Highlights From MSK Wednesday, October 1, 2025 Learn about some of the exciting research that MSK doctors and scientists presented at the 2025 Annual Meeting of the American Society for Radiation Oncology. Immunologist Chrysothemis Brown Named a 2025 Howard Hughes Medical Institute Freeman Hrabowski Scholar Wednesday, October 1, 2025 Dr. Brown, whose research has been shedding light on the development of the early life immune system and its relationship to autoimmunity, allergy, inflammation and cancer, was among 30 early career scientists nationwide selected for the 2025 class of scholars. Clinical Update Pembrolizumab for Locally Advanced Head and Neck Squamous Cell Carcinoma Approved by the FDA for Use Before and After Surgery Wednesday, October 1, 2025 Read about an FDA approval for immunotherapy to treat head and neck squamous cell carcinoma. To Study Treatment Resistance in High-Grade Serous Ovarian Cancer, MSK Researchers Develop New Approach Wednesday, October 1, 2025 An MSK research team aims to find new ways to stop the most common and deadly form of ovarian cancer — high-grade serous ovarian cancer — from recurring with the help of a method they developed for tracking the evolution of treatment resistant cells in ovarian cancer using blood tests. How MSK Doctors Are Using AI To Improve Radiation Treatment Friday, September 26, 2025 MSK researchers are leading the development of new artificial intelligence (AI) models to improve the targeting of radiation therapy — teaching computers to better isolate tumors and spare more of the surrounding healthy tissue. Article FDA Approves Imlunestrant to Stop Progression of ER+, HER2-, ESR1-mutated Advanced Breast Cancer That Resists Standard Therapy Thursday, September 25, 2025 Read about a new treatment for people with some ER+, HER2- advanced breast cancers. Pagination Load More Book traversal links for Newsroom Previous Newsroom Next Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment